Sling Therapeutics, Inc. closes $123 million Series C financing led by Forbion to advance Phase 3 development of its oral small molecule IGF-1R inhibitor for thyroid eye disease.
Amount Raised
$123 Million
Round Type
Series C
Ann ArborBiotechnologyHealth CareInvestors
Description
Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company, has closed a $123 million Series C financing. The financing was led by Forbion with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the continued clinical advancement of their therapy for thyroid eye disease.
Who to call at Sling Therapeutics, and when
A new round usually means Sling Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sling Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sling Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sling Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sling Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Sling Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.